HCV RNA assay sensitivity impacts the management of patients treated with direct-acting antivirals

Antiviral Therapy

Volumn 20, Issue 2, 2015, Pages 177-183

  Cloherty, Gavin ^a   Cohen, Daniel ^b   Sarrazin, Christoph ^c   Wedemeyer, Heiner ^d   Chevaliez, Stephane ^e,f   Herman, Christine ^a   Bernstein, Barry ^b   Pawlotsky, Jean Michel ^e,f  

^a Abbott Molecular Inc   (United States)

^b ABBVIE INC   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e UNIVERSITÉ PARIS EST CRÉTEIL   (France)

^f INSERM U955   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ABT 072; ANTIVIRUS AGENT; DASABUVIR; PARITAPREVIR; PEGINTERFERON; PLACEBO; RIBAVIRIN; UNCLASSIFIED DRUG; VIRUS RNA; ABT-333; ABT-450; ALPHA INTERFERON; DIAGNOSTIC KIT; MACROCYCLIC COMPOUND; MACROGOL DERIVATIVE; N-(3-AMINO-1-(CYCLOBUTYLMETHYL)-2,3-DIOXOPROPYL)-3-(2-((((1,1-DIMETHYLETHYL)AMINO)CARBONYL)AMINO)-3,3-DIMETHYL-1-OXOBUTYL)-6,6-DIMETHYL-3-AZABICYCLO(3.1.0)HEXAN-2-CARBOXAMIDE; OLIGOPEPTIDE; PEGINTERFERON ALPHA2A; PROLINE; RECOMBINANT PROTEIN; SULFONAMIDE; TELAPREVIR; URACIL;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DIAGNOSTIC KIT; DRUG SAFETY; DRUG TOLERABILITY; HCV RNA ASSAY; HEPATITIS C; HUMAN; HUMAN TISSUE; LIMIT OF DETECTION; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PREDICTIVE VALUE; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RESPONSE GUIDED THERAPY; SENSITIVITY ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE; VIRAL DISEASE IMMUNOFLUORESCENCE ASSAY; VIRUS LOAD; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; BIOASSAY; CLINICAL TRIAL; DRUG COMBINATION; DRUG EFFECTS; DRUG MONITORING; GENETICS; HEPACIVIRUS; HEPATITIS C, CHRONIC; PHYSIOLOGY; RANDOMIZED CONTROLLED TRIAL; SENSITIVITY AND SPECIFICITY; STANDARDS; TREATMENT OUTCOME; VIROLOGY;

ANTIVIRAL AGENTS; BIOLOGICAL ASSAY; DRUG MONITORING; DRUG THERAPY, COMBINATION; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; MACROCYCLIC COMPOUNDS; OLIGOPEPTIDES; POLYETHYLENE GLYCOLS; PROLINE; REAGENT KITS, DIAGNOSTIC; RECOMBINANT PROTEINS; RIBAVIRIN; RNA, VIRAL; SENSITIVITY AND SPECIFICITY; SULFONAMIDES; TREATMENT OUTCOME; URACIL; VIRAL LOAD;

EID: 84937558295     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2810     Document Type: Article

References (28)

1. Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis 2005; 5:558-567.
2. The Global Burden of Hepatitis C Working Group. Global burden of disease (GBD) for hepatitis C. J Clin Pharmacol 2004; 44:20-29.
3. Wise M, Bialek S, Finelli L, Bell BP, Sorvillo F. Changing trends in hepatitis C-related mortality in the United States, 1995-2004. Hepatology 2008; 47:1128-1135.
4. Ghany MG, Strader DB, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology 2009; 49:1335-1374.
5. Jensen DM, Morgan TR, Marcellin P, et al. Early identification of HCV genotype 1 patients responding to 24 weeks peginterferon alpha-2a (40 kd)/ribavirin therapy. Hepatology 2006; 43:954-960.
6. Ferenci P, Laferl H, Scherzer TM, et al. Peginterferon alfa-2a and ribavirin for 24 weeks in hepatitis C type 1 and 4 patients with rapid virological response. Gastroenterology 2008; 135:451-458.
7. Harrington PR, Zeng W, Naeger LK. Clinical relevance of detectable but not quantifiable hepatitis C virus RNA during boceprevir or telaprevir treatment. Hepatology 2012; 55:1048-1057.
8. Merck Sharp & Dohme Corporation. VICTRELIS® (boceprevir) capsules for oral use: highlights of prescribing information. (Updated November 2012. Accessed 8 January 2013.) Available from http://www.merck.com/product/usa/pi-circulars/v/victrelis/victrelis-pi.pdf
9. Vertex Pharmaceuticals Incorporated. INCIVEKTM (telaprevir) film coated tablets, for oral use: highlights of prescribing information. (Updated October 2012. Accessed 8 January 2013.) Available from http://pi.vrtx.com/files/uspi-telaprevir.pdf
10. Jacobson IM, Marcellin P, Zeuzem S, et al. Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin. Hepatology 2012; 56:567-575.
11. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 2011; 365:1014-1024.
12. Chevaliez S, Rodriguez C, Pawlotsky JM. New virologic tools for management of chronic hepatitis B and C. Gastroenterology 2012; 142:1303-1313.
13. Farnik H, Zeuzem S. New antiviral therapies in the management of HCV infection. Antivir Ther 2012; 17:771-783.
14. Stedman CA. Current prospects for interferon-free treatment of hepatitis C in 2012. J Gastroenterol Hepatol 2013; 28:38-45.
15. Ciesek S, von Hahn T, Manns MP. Second-wave protease inhibitors: choosing an heir. Clin Liver Dis 2011; 15:597-609.
16. Sarrazin C, Hézode C, Zeuzem S, Pawlotsky J-M. Antiviral strategies in hepatitis C virus infection. J Hepatol 2012; 56 Suppl 1:S88-S100.
17. Wedemeyer H, Jensen DM, Godofsky E, Mani N, Pawlotsky JM, Miller V. Recommendations for standardized nomenclature and definitions of viral response in trials of HCV investigational agents. Hepatology 2012; 56:2398-2403.
18. LaRue H, Rigali L, Balada-Llasat JM, Pancholi P. Performance of the Abbott RealTime and Roche Cobas TaqMan hepatitis C virus (HCV) assays for quantification of HCV genotypes. J Clin Microbiol 2012; 50:1769-1772.
19. Laperche S, Bouchardeau F, Andre-Garnier E, et al. Interpretation of real-time PCR results for hepatitis C virus RNA when viral load is below quantification limits. J Clin Microbiol 2011; 49:1113-1115.
20. Pyne MT, Konnick EQ, Phansalkar A, Hillyard DR. Evaluation of the Abbott investigational use only RealTime hepatitis C virus (HCV) assay and comparison to the Roche TaqMan HCV analyte-specific reagent assay. J Clin Microbiol 2009; 47:2872-2878.
21. Pisani G, Cristiano K, Marino F, et al. Quantification of hepatitis C virus (HCV) RNA in a multicenter study: implications for management of HCV genotype 1-infected patients. J Clin Microbiol 2009; 47:2931-2936.
22. Vermehren J, Kau A, Gartner BC, Gobel R, Zeuzem S, Sarrazin C. Differences between two real-time PCR-based hepatitis C virus (HCV) assays (RealTime HCV and Cobas AmpliPrep/Cobas TaqMan) and one signal amplification assay (Versant HCV RNA 3.0) for RNA detection and quantification. J Clin Microbiol 2008; 46:3880-3891.
23. Tuaillon E, Mondain AM, Ottomani L, et al. Impact of hepatitis C virus (HCV) genotypes on quantification of HCV RNA in serum by COBAS AmpliPrep/COBAS TaqMan HCV test, Abbott HCV RealTime assay [corrected] and VERSANT HCV RNA assay. J Clin Microbiol 2007; 45:3077-3081.
24. Michelin BD, Muller Z, Stelzl E, Marth E, Kessler HH. Evaluation of the Abbott RealTime HCV assay for quantitative detection of hepatitis C virus RNA. J Clin Virol 2007; 38:96-100.
25. Halfon P, Bourliere M, Penaranda G, Khiri H, Ouzan D. Real-time PCR assays for hepatitis C virus (HCV) RNA quantitation are adequate for clinical management of patients with chronic HCV infection. J Clin Microbiol 2006; 44:2507-2511.
26. Chevaliez S, Bouvier-Alias M, Brillet R, Pawlotsky JM. Overestimation and underestimation of hepatitis C virus RNA levels in a widely used real-time polymerase chain reaction-based method. Hepatology 2007; 46:22-31.
27. Colucci G, Ferguson J, Harkleroad C, et al. Improved COBAS TaqMan hepatitis C virus test (Version 2.0) for use with the High Pure system: enhanced genotype inclusivity and performance characteristics in a multisite study. J Clin Microbiol 2007; 45:3595-3600.
28. Zitzer H, Heilek G, Truchon K, et al. Second-generation Cobas AmpliPrep/Cobas TaqMan HCV Quantitative Test for viral load monitoring: a novel dual-probe assay design. J Clin Microbiol 2013; 51:571-577.